With today's excellent cure rates for Hodgkin lymphoma (HL), the number of long-term survivors is increasing. This study aims to provide a global assessment of late adverse effects for workingage HL survivors treated with contemporary protocols (combination chemotherapy and limited radiotherapy). From Swedish nationwide registers we identified 1017 HL survivors diagnosed in 2000-2009, aged 18-60 years (median 32) and surviving at least one year post-diagnosis, and 4031 age-, sex-, and calendar-year-matched population comparators. Incidence rate ratios (IRR) and 95% confidence intervals (95%CI) for outpatient visits and inpatient bed-days after the first year up to 14 years post-diagnosis (through 2013) were estimated across treatment subgroups, considering relapse-free time and using negative binomial regression. Scheduled outpatient visits for HL were excluded. The rate of outpatient visits was nearly double (IRR 5 1.8, 95%CI: 1.6-2.0) that among comparators and higher rates persisted up to 10 years post-diagnosis. The rate of inpatient bed-days among relapse-free survivors was more than three-fold (IRR 5 3.6, 95%CI: 2.7-4.7) that of comparators and the increase persisted up to four years post-diagnosis. Patients requiring 6-8 chemotherapy courses had higher rates of outpatient visits (IRR 5 1.4, 95%CI: 1.1-1.7) and bed-days (IRR 5 4.7, 95%CI: 2.9-7.8) than patients treated with 2-4 courses 1 radiotherapy. Previously seldom reported reasons for the excess healthcare use included chest pain, keratitis, asthma, diabetes mellitus, and depression. Contemporary treatment, chemotherapy in particular, was associated with excess healthcare use among HL survivors during the first decade postdiagnosis. The reasons for healthcare visits reflected a wide range of disorders, indicating the need of broad individualized care in addition to specific screening programs.
Radiotherapy-associated second malignancies and cardiovascular disease typically occur with long induction times of >15 years. 2, 7 Since involved field/node irradiation and contemporary chemotherapy regimens were introduced in clinical routine in the mid-to late 1990s, 8 it is still challenging to evaluate potential changes in risk of these severe complications due to insufficient follow-up time. Meanwhile, chemotherapy-related complications occurring during the first decade after diagnosis can substantially affect the quality of life during reproductive 9 and working ages among young survivors 10 and can, in combination with normal aging, cause a wide range of diseases/symptoms in elderly. 11 Traditionally, long-term complications after HL diagnosis and treatment, such as heart disease, [12] [13] [14] [15] secondary malignancies, [16] [17] [18] fatigue, 19, 20 and health-related quality of life, 21, 22 have been studied separately by disease or symptom group. As concluded by Straus et al., 23 there is a lack of global assessments of both somatic and psychiatric diagnoses for patients treated with contemporary protocols.
Previous register-based studies evaluating outpatient visits and inpatient bed-days for adult HL survivors are rare, 12,24-27 but they provide an excellent view of the global late adverse effects and they minimize selection bias, which can undermine the validity of questionnaire-based studies. These previous studies, however, covered older eras. Therefore, the aim of this study was to explore the panorama of late adverse effects following the introduction of contemporary treatment protocols for HL through a comprehensive assessment of the extent and causes of non-primary outpatient visits and inpatient bed-days among HL survivors versus matched comparators.
| M E T H O D S

| Study population
We identified all HL patients diagnosed at ages who eventually encountered a relapse were followed until the relapse date and were then censored. In a sensitivity analysis, we brought forward the date of the end of follow-up by 90 days for cases (and comparators) to remove visits/bed-days that were possibly attributable to early symptoms of HL relapse.
In an exploratory analysis, we summarized main diagnoses of outand inpatient use in ICD-10 chapters separately for cases and comparators, as recorded in the National Patient Register. Lists of the five most common diagnoses within each disease group over the entire followup period were summarized descriptively in terms of counts and unadjusted incidence rates (per 1 000 person-years). In this exploration, inpatient visits instead of bed-days were used. No hypothesis testing was performed for this analysis.
| ETHICS
The study was approved by the regional ethics review board in Stockholm, Sweden, according to the Helsinki Declaration.
| R E S U LTS
Among the 1 017 HL survivors and their 4031 comparators, the median age at diagnosis/match year was 32 years (range 18-60; Table   1 ). Survivors and comparators were similarly distributed with regard to education level and the matching factors. During a median follow-up of eight years post-diagnosis (maximum 14 years), the rate of specialist outpatient visits was nearly double for relapse-free HL survivors versus
and the rate of bed-days was over three times higher (IRR 5 3.6, 95
%CI 5 2.7-4.7). These differences were observed among both men and women and remained up to 10 years post-diagnosis for outpatient visits, and up to four years postdiagnosis for bed-days. In absolute terms, survivors had on average 6.6 outpatient visits and 5.9 bed-days over follow-up, as compared with 4.4 outpatient visits and 3.2 bed-days for comparators (Table 1) (Table 2) . Forty percent of advanced-stage patients had a least one bed-day during follow-up compared with 32% among limited stages. Similarly, survivors given 6-8 ABVD-or BEACOPP chemotherapy courses had a higher rate of outpatient visits and bed-days than survivors who were given 2-4 courses of ABVD 6 radiotherapy. Irradiated survivors had fewer bed-days than those treated with full chemotherapy and no radiotherapy ( Table 2 ).
There was no statistical difference in the IRRs comparing 6-8 BEA-COPP to 6-8 ABVD, outpatient visits (IRR 5 1.1, 95%CI 5 0.9-1.5) and bed-days (IRR 5 1.8, 95%CI 5 0.9-3.7).
Bringing forward the last date of follow up by 90 days, lowered the number of visits and bed-days slightly but did not alter the main results (data not shown).
| Reasons for outpatient visits
In an exploratory comparison of diagnoses of visits, the excess healthcare use was reflected in a broad panorama of diseases ( Figure 1B ). As expected, HL survivors had more outpatient visits than comparators for non-HL neoplasms, including both benign and malignant tumors ( Figure 1A , Supporting Information Table SII) . Overall, acute myeloid leukemia (AML) and brain tumors were among the five most common non-HL malignancies for survivors (Supporting Information Table SII ).
Up to the fourth year, the most common reasons for tumor-related outpatient visits were AML (n 5 44 visits), melanocytic nevi (n 5 26), lung cancer (n 5 19), tumors in the rhinopharynx (n 5 14), and myelodysplastic syndrome (n 5 13). Outpatient visits for circulatory diseases were more common among survivors than comparators during years one through six. Otherwise, up to six years postdiagnosis, survivors were attended more often than comparators for infections, especially viral infections (HIV, herpes zoster, and condyloma; Supporting Information Table SII) , mental disorders (depression and acute stress reaction); respiratory disorders (infections, asthma and pneumonia);
genitourinary diseases (infertility and postmenopausal bleeding); and certain nonspecific symptoms (chest pain and dyspnea). Survivors also were seen somewhat more often for endocrine disorders (mainly diabetes mellitus, thyroid, and testicular dysfunction), eye disorders (keratitis), skin, and musculoskeletal diseases ( Figure 1B ).
| Reasons for inpatient bed-days
Inpatient bed-days with HL as main diagnosis accounted for most of the discrepancy between relapse-free survivors and comparators up to four years postdiagnosis (n 5 114 visits; Figure 2A , Supporting Information Table SII ). Other tumor-related reasons for inpatient visits were for acute leukemia (n 5 15) and tumors in the rhinopharynx (n 5 7). HL survivors also were hospitalized more often than comparators for infections (septicemia, viral infections, and erysipelas; Supporting Information Table SII) ; respiratory disorders (pneumonia); genitourinary diseases (nephritis, nephrolithiasis, and urinary infections); nonspecific symptoms (chest pain and fever), and injuries ( Figure 2B ).
| DISCUSSION
In this population-based study, relapse-free HL survivors experienced higher rates of outpatient visits than matched population comparators for up to 10 years post-diagnosis and more bed-days for up to 4 years.
On average, however, this difference, translated into relatively few absolute excess visits and bed-days. While well-established late effects from treatment, including neoplasms, infections and respiratory diseases, were prominent reasons for visits, the burden of other less commonly reported conditions such as depression, diabetes mellitus, asthma, genitourinary diseases, and skin diseases also appeared to be higher for survivors than comparators generating hypotheses for further study. The higher relative rates of outpatient visits and bed-days were most pronounced for intensively chemotherapy-treated patients and they were not explained by HL relapse.
Most previous studies on hospitalizations in cancer survivors have focused on all malignancies combined. 27, [36] [37] [38] In the few studies reporting separate results for HL survivors, [24] [25] [26] [27] only two presented a global assessment of long-term adverse effects, 26, 27 and both were conducted during time periods when older treatments were used. 26, 27 In line with our findings, Rugbjerg et al. described a 85% higher risk of hospitalization in 15-to 39-year-old HL patients who had survived at least five years versus comparators. 27 Previously seldomly reported somatic diagnoses that appeared to be more frequent among survivors in the current investigation were respiratory diseases (e.g., asthma), depression, genitourinary diseases (not only explained by infertility 9, [39] [40] [41] [42] [43] [44] ), nonspecific symptoms (e.g., chest pain), musculoskeletal disorders (e.g., autoimmune diseases and pain), skin diseases (e.g., eczema) and eye disorders (e.g., keratitis, possibly related to infections or immune deficiency). Some of these diseases/symptoms are likely related to the HL treatment whereas some co-occurrence may be explained by shared susceptibility or risk factors. 45 An increased risk of infections, especially with viral agents, pneumonia and septicaemia has also been described subsequent to older HL treatments. 46, 47 A higher rate of visits for endocrine diseases, such as thyroid dysfunction, a well-known complication of radiotherapy, 1 is expected, but more visits for diabetes mellitus was not expected. One previous questionnaire study investigated risk of endocrine disorders in 117 HL survivors and compared the results with the estimated frequency in the German population. Here, diabetes was reported more frequently by male HL patients. 48 More diabetes in HL survivors were also reported after para-aortic radiation with 36 Gray, explained by higher dose to the pancreatic tail. 49 In line with others, we observed an increased number of visits for a wide range of benign and malignant tumors 1,2,7 also relatively shortly after diagnosis. Certain severe diseases, such as AML, can result in a high number of visits by relatively few individuals. Our results indicate that the excess risk of neoplasms in HL survivors in the short-to medium-term perspective is likely caused by a combination of and bed-days due to circulatory diseases between six to 14 years postdiagnosis. Young HL patients treated with modern protocols have low excess mortality from cardiovascular diseases. 13 The older chemotherapy regimens (MOPP) are not necessarily more cardiotoxic than ABVD, but older radiotherapy including larger volumes of the heart, are known for their higher risk of late cardiac events compared with today's limited volumes, more accurate targeting and sparing of normal tissue. 52 Although cautious interpretation is needed due to the relatively short follow-up, Table S1 contemporary treatments might be associated with a lower degree of cardiovascular complications. No patients in the current cohort were treated with the large mantle radiation beams previously used.
The major strengths are the use of population-based registers to enable comprehensive evaluation of specialist outpatient visits and beddays, and the ability to focus the analysis on relapse-free HL patients treated according to modern principles. Some misclassification of ICDcodes, and underreported relapse data could have had a minor influence on results, but the validity of the Swedish National Patient Register is high. 53 Although all factors that affect the general well-being cannot be captured through nonprimary care outpatient visits, which may underestimate the risk of less severe health issues, our results generate useful hypotheses for future studies. Finally, since the duration of follow-up was fairly limited, the risk of very late adverse effects of the disease and the contemporary treatment regimens still remains to be evaluated. 
